首页> 外文期刊>Expert opinion on pharmacotherapy >Survey to determine the efficacy and safety of guideline-based pharmacological therapy for chronic obstructive pulmonary disease patients not previously receiving maintenance treatment
【24h】

Survey to determine the efficacy and safety of guideline-based pharmacological therapy for chronic obstructive pulmonary disease patients not previously receiving maintenance treatment

机译:确定基于指南的药物治疗对先前未接受维持治疗的慢性阻塞性肺疾病患者的疗效和安全性的调查

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To investigate the potential beneficial effects of guideline-based pharmacological therapy on pulmonary function and quality of life (QOL) in Japanese chronic obstructive pulmonary disease (COPD) patients without prior treatment.Research design and methods: Multicenter survey, open-label study of 49 Japanese COPD patients aged 40 years; outpatients with >10 pack years of smoking history; ratio of forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 70%; predicted FEV1 < 80%; treated with bronchodilators and/or inhaled corticosteroids as maintenance therapy until week 48.Main outcome measures: The primary endpoint was change in pulmonary function (trough FEV1, trough FVC); secondary endpoints were QOL and physical activity at 48 weeks after initiation of therapy.Results: Airway reversibility was confirmed in untreated patients. Significant changes over time were not observed for FEV1 and FVC, indicating lung function at initiation of treatment was maintained during the observation period. COPD assessment test scores showed statistical and clinical improvements. Cough, sputum, breathlessness, and shortness of breath were significantly improved.Conclusions: Lung function and QOL of untreated Japanese COPD patients improved and improvements were maintained by performing a therapeutic intervention that conformed to published guidelines.
机译:目的:探讨基于指南的药物治疗对未经事先治疗的日本慢性阻塞性肺疾病(COPD)患者的肺功能和生活质量(QOL)的潜在有益效果。研究设计和方法:多中心调查,开放标签研究日本49名40岁的COPD患者;吸烟史超过10年的门诊患者; 1秒内呼气量(FEV1)/肺活量(FVC)的比率<70%;预测FEV1 <80%;主要结果指标:主要终点是肺功能的改变(波谷FEV1,波谷FVC);次要终点是治疗开始后48周的QOL和身体活动。结果:未经治疗的患者已确认气道可逆性。 FEV1和FVC未观察到随时间的显着变化,这表明在观察期间维持治疗开始时的肺功能。 COPD评估测试成绩显示出统计学和临床​​上的改善。结论:未经治疗的日本COPD患者的肺功能和生活质量得到改善,并且通过执行符合已发布指南的治疗干预得以维持,从而改善了咳嗽,咳痰,呼吸困难和呼吸急促。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号